Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 46Melanoma 34Carcinoma, Renal Cell 29Neoplasm Metastasis 25Neoplasms 24Esophageal Neoplasms 24Colonic Neoplasms 22Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Transitional Cell 20Liver Neoplasms 19Ovarian Neoplasms 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Triple Negative Breast Neoplasms 15Rectal Neoplasms 15Breast Neoplasms 14Biliary Tract Neoplasms 14Uterine Cervical Neoplasms 13Lung Neoplasms 12Cholangiocarcinoma 12Carcinoma, Merkel Cell 12Head and Neck Neoplasms 10Prostatic Neoplasms 9Gastrointestinal Neoplasms 9Small Cell Lung Carcinoma 8Endometrial Neoplasms 8

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × Nivolumab × Gastrointestinal × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡